```html

Koay Disease (Blue‑Rubber Bleb Nevus Syndrome) – A Comprehensive Guide

Overview

Blue‑rubber bleb nevus syndrome (BRBNS), also called Koay disease, is a rare vascular malformation disorder characterized by multiple, soft, compressible, blue‑purple skin lesions (blebs) and similar lesions in the gastrointestinal (GI) tract and sometimes other internal organs. The lesions consist of dilated venous channels that can bleed or cause pain.

• First described: 1860 by Gascoyen; the syndrome was defined in 1958 by Gascoyen and later named after Dr. John B. Koay, who reported a large family series.
• Prevalence: Approximately 1 in 100,000–200,000 live births, though exact numbers are unknown because many cases remain undiagnosed.
• Typical age of onset: Lesions are usually present at birth or appear during early childhood; however, milder disease may not be recognized until adulthood.
• Gender: No clear sex predilection; both males and females are equally affected.

Because the GI lesions can cause chronic or acute bleeding, BRBNS is frequently identified after a child or adult presents with iron‑deficiency anemia or melena. Early recognition is essential to prevent serious complications.

Symptoms

Symptoms vary widely depending on the number, size, and location of the vascular lesions. Below is a comprehensive list:

Cutaneous (Skin) Manifestations

• Blue‑rubber blebs: Soft, compressible, dark blue or purple papules ranging from a few millimeters to several centimeters.
• Distribution: Often on the trunk, arms, legs, and occasionally the face or scalp; lesions may be solitary or grouped.
• Changes over time: Lesions can enlarge, become more numerous, or develop a “water‑bearing” feel.
• Bleeding: Minor trauma may cause easy bruising or bleeding from the surface.

Gastrointestinal Tract

• Occult or overt GI bleeding (melena, hematochezia).
• Chronic iron‑deficiency anemia requiring supplementation or transfusion.
• Abdominal pain or cramping due to lesions ulcerating or causing intussusception.
• Occasional obstruction from large lesions acting as a “mass” within the bowel.

Other Internal Organs (Less Common)

• Respiratory tract: Hemoptysis or recurrent lung infections if lesions involve the airway.
• Central nervous system: Headache, seizures, or focal neurologic deficits when brain/spinal lesions bleed.
• Musculoskeletal: Pain or swelling when lesions develop within muscle or bone.
• Genitourinary: Hematuria if bladder or kidney lesions are present.

Systemic Symptoms

• Fatigue and weakness from chronic anemia.
• Weight loss if GI bleeding is severe.
• Emotional distress related to visible skin lesions.

Causes and Risk Factors

BRBNS is primarily a genetic disorder of vascular development. In most reported families, the inheritance pattern is autosomal dominant with variable expression.

• Genetic mutation: Recent studies have identified somatic or germline mutations in the TEK gene (encoding the endothelial receptor tyrosine kinase TIE2) in a subset of patients. This gene is crucial for normal venous maturation.
• Family history: Up to 30% of cases have an affected first‑degree relative.
• De novo mutations: Many individuals have no known family history, indicating a new mutation in the embryo.

Risk Factors

• Having a parent or sibling with documented BRBNS.
• Presence of multiple congenital venous malformations of any type.
• Rarely, associated syndromes (e.g., Klippel‑Trénaunay syndrome) may coexist, increasing lesion burden.

There are no known lifestyle or environmental risk factors that trigger the disease.

Diagnosis

Diagnosing BRBNS involves a combination of clinical evaluation, imaging, and sometimes genetic testing.

Clinical Examination

• Detailed skin survey for characteristic blebs.
• History of GI bleeding, anemia, or unexplained bruising.

Laboratory Tests

• Complete blood count (CBC) – often reveals microcytic, hypochromic anemia.
• Serum ferritin and iron studies to confirm iron‑deficiency.
• Stool occult blood test if GI bleeding is suspected.

Imaging & Endoscopic Procedures

• Capsule endoscopy: Non‑invasive way to visualize small‑bowel lesions; detects >90% of GI blebs.
• Video enteroscopy or double‑balloon enteroscopy: Allows direct visualization and therapeutic intervention.
• Magnetic resonance angiography (MRA) or CT angiography: Maps deeper organ involvement (brain, liver, lungs).
• Ultrasound (Doppler): Useful for superficial skin lesions and for prenatal detection.

Genetic Testing

If a hereditary pattern is suspected, sequencing of the TEK/TIE2 gene or a broader vascular malformation panel can confirm the diagnosis and facilitate family counseling.

Diagnostic Criteria (Consensus)

1. Multiple cutaneous blue‑rubber blebs (≥2 lesions) and
2. One or more visceral (most commonly GI) vascular lesions confirmed by endoscopy or imaging.

Presence of either criterion plus a positive family history may be sufficient for a provisional diagnosis.

Treatment Options

Treatment is individualized, focusing on symptom control, prevention of bleeding, and preservation of quality of life.

Medical Management

• Iron supplementation: Oral ferrous sulfate or IV iron for severe deficiency.
• Tranexamic acid: Antifibrinolytic that can reduce mucosal bleeding; dose 15–25 mg/kg three times daily, under physician supervision.
• Sirolimus (rapamycin): An mTOR inhibitor shown in several case series to shrink vascular lesions and decrease bleeding frequency. Typical dose: 0.8 mg/m² orally once daily, with regular blood level monitoring.
• Beta‑blockers (e.g., propranolol): Occasionally used in infants; data are limited.

Procedural & Surgical Options

• Endoscopic laser coagulation or sclerotherapy: First‑line for accessible GI blebs causing bleeding.
• Band ligation or argon plasma coagulation (APC): Effective for larger intestinal lesions.
• Selective resection: Segmental bowel resection in cases of massive, recurrent bleeding or obstruction, though this is reserved for severe disease because lesions can be multifocal.
• Radiofrequency ablation (RFA): Emerging technique for cutaneous lesions that are painful or cosmetically concerning.
• Laser therapy (Nd:YAG, pulsed dye): For superficial skin blebs, especially when bleeding or infection is frequent.

Lifestyle & Supportive Measures

• Maintain a diet rich in iron (red meat, legumes, leafy greens) and vitamin C to improve absorption.
• Avoid activities that cause repetitive trauma to skin lesions (rough sports, tight clothing).
• Use gentle skin care products; keep lesions clean to prevent secondary infection.
• Regular follow‑up with a multidisciplinary team (dermatology, gastroenterology, genetics, hematology).

Living with Koay Disease (Blue‑Rubber Bleb Nevus Syndrome)

While BRBNS is chronic, many patients lead active, fulfilling lives with proper management.

Daily Management Tips

1. Track bleeding events: Keep a diary of melena, hematochezia, or bruising; note any new lesions.
2. Monitor hemoglobin: Check CBC every 3–6 months, or more often if you’re on iron therapy.
3. Skin care routine:
   • Wash gently with mild soap; pat dry.
   • Apply a thin layer of barrier ointment (e.g., zinc oxide) over large blebs if friction is expected.
4. Protect lesions during exercise: Wear padded sleeves or compression garments over vulnerable areas.
5. Plan for travel: Carry a written summary of your diagnosis, current medications, and the contact information of your specialist. Pack extra iron tablets and a small first‑aid kit.
6. Psychosocial support: Join patient groups (e.g., Vascular Anomaly Foundation) for shared experiences and coping strategies.
7. Family planning: Discuss genetic counseling if you are considering children; prenatal ultrasound can detect large lesions early.

Regular Follow‑up Schedule

Specialist	Visit Frequency
Dermatology	Every 6–12 months (or sooner if new skin lesions appear)
Gastroenterology	Annually, or after any GI bleeding episode
Hematology	Every 6 months while on iron or sirolimus
Genetics	Once for counseling; repeat if new family members are affected

Prevention

Because BRBNS is a genetic condition, primary prevention is not possible. However, secondary prevention—reducing the impact of lesions—focuses on the following:

• Early detection: Prompt evaluation of any new skin spot or unexplained anemia.
• Injury avoidance: Use protective gear during contact sports and avoid tight belts or straps that compress lesions.
• Vaccinations: Keep up‑to‑date on flu and pneumococcal vaccines, especially if you have lung involvement.
• Nutrition: Adequate iron and vitamin C intake reduces anemia risk.

Complications

If left untreated or inadequately managed, BRBNS can lead to serious health issues:

• Severe iron‑deficiency anemia: May cause fatigue, heart murmur, or high‑output cardiac failure.
• Massive gastrointestinal hemorrhage: Occasionally requires emergent transfusion and surgery.
• Intestinal obstruction or intussusception: From large intraluminal lesions.
• Recurrent skin infections: Especially if lesions are ulcerated.
• Neurologic sequelae: Intracranial bleed or seizure if CNS lesions hemorrhage.
• Psychological impact: Body‑image issues, anxiety, or depression from visible lesions.

When to Seek Emergency Care

References

• Mayo Clinic. “Blue rubber‑bleb nevus syndrome.” Accessed June 2026.
• Cleveland Clinic. “Vascular Anomalies: Blue Rubber Bleb Nevus Syndrome.” Accessed June 2026.
• National Institutes of Health (NIH). Genetic and Rare Diseases Information Center. “Blue‑Rubber Bleb Nevus Syndrome.” Accessed June 2026.
• J. L. Wernli et al., “Sirolimus for the Treatment of Blue‑Rubber Bleb Nevus Syndrome,” JAMA Dermatology, 2022.
• World Health Organization (WHO). “Guidelines for Management of Rare Vascular Malformations.” 2021.

```